News 25th March 2021 – Formulation Options in Nasal Drug Delivery The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to … Read more
The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in growing interest from scientists looking to administer both therapeutic agents and vaccines via the nasal delivery … Read more
News 1st December 2020 – Manufacturing Clinical Supplies: The Early Phase Clinical Manufacture Timeline Whilst undergoing research and development on a new chemical entity / new biological entity there are major initial objectives when planning the roadmap to clinic, submission and approval of the regulatory documentation, and ultimately dosage form administration in a human clinical … Read more
News 10th November 2020 – Manufacturing Clinical Supplies: Planning a First in Human Study Clinical trials are one of the most important components of any drug development project; requiring careful planning and extensive funding. Clinical trials are conducted to improve the efficacy and quality of a drug, to determine the dose and dose escalation, and … Read more
News 27th October 2020 – Manufacturing Clinical Supplies: The Role of Placebos and the Challenges of Manufacturing they Present One aspect of clinical trial manufacturing that often slips under the radar when designing, planning, and budgeting a clinical study is the role and supply of the placebo control. A placebo is defined as a substance … Read more
Drug administration via the nasal route can be used as an efficient method of administration for both local and systemic acting drugs. The nasal route offers a range of advantages including its relative ease of use as compared to injectable administration, patient acceptability and compliance. It also provides a suitable route for those compounds that … Read more
News 21st July 2020 – Considerations when Developing Dry Powder Formulations for Nasal Locally Delivered Drugs By 2020, 58% of all therapeutics in development are injectable, 29% oral and 4% inhaled including nasal delivery, and while nasal delivery may not be one of the most explored routes, it has the potential to offer an alternative … Read more
News 9th June 2020 – Nasal Delivery: An Alternative Route As of March 2020, 58% of all therapeutics in development are injectable, 29% oral and 4% inhaled including nasal delivery, and while nasal delivery may not be one of the most explored routes, it holds the potential to offer an alternative delivery method for therapeutics … Read more
News 12th May 2020 – A Tablet Development Journey at Upperton With the continued expansion of our tablet formulation development services, Upperton currently have a number of tablet dosage form development projects completed or in progress. Theses tablet / solid dosage form projects have encompassed a wide range of development activities from Active Pharmaceutical Ingredient … Read more
29th April 2020 – Press Release Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) have invested £500K in significantly expanding their tablet manufacturing capabilities with the addition of tablet processing equipment for wet granulation, roller compaction, tablet compression, hardness testing, dedusting, weight sorting and tablet coating throughout 2019 and 2020. This investment … Read more
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK NG7 2TN,
Phone: +44 (0) 115 855 7050
Email: contact@upperton.com
Copyright © 2024 Upperton Limited. All rights reserved.
